Treatment guidelines and consensus statements for the treatment of migraine has been published by The American Academy of Neurology (AAN), jointly with several organisations including the American Headache Society (AHS), and by the European Headache Federation (EHF), endorsed by the European Academy of Neurology. Several classes of therapy are now deemed either effective or probably effective for the treatment of migraine. [Ailani et al., 2021; Eigenbrodt et al., 2021; Silberstein, 2000]
Several therapies has been dismissed as ineffective, and for several more therapies there was insufficient evidence on which to make a conclusion.[Marmura et al., 2015] The guidelines and consensus statements make clear that there are considerations beyond efficacy alone; for example, certain opioids are not recommended for use in Canada, Australia and Europe because of the potential for adverse events, and adverse drug–drug interactions.[Eigenbrodt et al., 2021; Marmura et al., 2015]